Environmental Risk Assessment (ERA) of diclofenac and ibuprofen: a public health perspective.

Non-steroidal anti-inflammatory drugs (NSAIDs) have been widely used in human and veterinary medicine, representing potential aquatic environmental contamination. This study aimed to perform an Environmental Risk Assessment (ERA) of NSAIDs diclofenac (Dic) and ibuprofen (Ibu) in cities of the state of Paraná, Brazil, over the course of three years, by using available data from the Brazilian Public Health System. The environmental risk (ER) was assessed by employing the European Medicines Agency (EMeA) approach, and predicted environmental concentrations (PECs) were calculated. The refined PECs considered the drug metabolism and the excretion data, and also the sewage treatment plant removal rates of biological filters and activated sludge processes to define environmental scenarios. References to the predicted no effect concentration (PNEC) for these pharmaceuticals were considered, and the PEC/PNEC ratio was calculated; ratio values ⩾ 1 suggested an ER. Environmental risk was conducted on several cities, and the lack of an adequate sanitation system in the majority of Paraná cities forecasts a significant concern with the exposure to possible environmental damages in those cities. The high PEC/PNEC ratios in several cities showed that current usage patterns of these drugs constitute an environmental issue in need of resolution by health and environmental authorities.

[1]  Karin Treyer,et al.  Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater. , 2011, Water research.

[2]  G. Ying,et al.  Occurrence and risk assessment of acidic pharmaceuticals in the Yellow River, Hai River and Liao River of north China. , 2010, The Science of the total environment.

[3]  M. Cleuvers.  Aquatic ecotoxicity of pharmaceuticals including the assessment of combination effects. , 2003, Toxicology letters.

[4]  K Kümmerer,et al.  Drugs in the environment: emission of drugs, diagnostic aids and disinfectants into wastewater by hospitals in relation to other sources--a review. , 2001, Chemosphere.

[5]  D. Barceló,et al.  Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. , 2010, Environment international.

[6]  K Kümmerer,et al.  Promoting resistance by the emission of antibiotics from hospitals and households into effluent. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  Ettore Zuccato,et al.  Presence of therapeutic drugs in the environment , 2000, The Lancet.

[8]  Carina Carlsson,et al.  Are pharmaceuticals potent environmental pollutants? Part II: environmental risk assessments of selected pharmaceutical excipients. , 2006, The Science of the total environment.

[9]  N. Voulvoulis,et al.  Household disposal of pharmaceuticals and perception of risk to the environment. , 2006, Environmental toxicology and pharmacology.

[10]  D. Dietrich,et al.  Hindsight rather than foresight: reality versus the EU draft guideline on pharmaceuticals in the environment. , 2004, Trends in biotechnology.

[11]  G. Huschek,et al.  Environmental risk assessment of medicinal products for human use according to European Commission recommendations , 2004, Environmental toxicology.

[12]  K. Yetilmezsoy,et al.  Appraisal of potential environmental risks associated with human antibiotic consumption in Turkey. , 2009, Journal of hazardous materials.

[13]  A. Pollio,et al.  Environmental risk assessment of six human pharmaceuticals: Are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment? , 2004, Environmental toxicology and chemistry.

[14]  Stuart J Khan,et al.  Modelling of pharmaceutical residues in Australian sewage by quantities of use and fugacity calculations. , 2004, Chemosphere.

[15]  E. Heath,et al.  Removal of pharmaceutical residues in a pilot wastewater treatment plant , 2007, Analytical and bioanalytical chemistry.

[16]  M. Birkved,et al.  Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. , 2000, Chemosphere.

[17]  Anna-Karin Johansson,et al.  Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients. , 2006, The Science of the total environment.

[18]  N Voulvoulis,et al.  Pharmaceuticals in the aquatic environment--a comparison of risk assessment strategies. , 2004, Chemosphere.

[19]  A. Boxall.  The environmental side effects of medication , 2004, EMBO reports.

[20]  M. Dezotti,et al.  Fármacos no meio ambiente , 2003 .

[21]  T. Ternes.  Occurrence of drugs in German sewage treatment plants and rivers 1 Dedicated to Professor Dr. Klaus , 1998 .

[22]  C. Daughton.  Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy. , 2003, Environmental health perspectives.

[23]  T. Ternes,et al.  Polar drug residues in sewage and natural waters in the state of Rio de Janeiro, Brazil. , 1999, The Science of the total environment.

[24]  Heinz P Singer,et al.  Occurrence and fate of carbamazepine, clofibric acid, diclofenac, ibuprofen, ketoprofen, and naproxen in surface waters. , 2003, Environmental science & technology.

[25]  Oliver A.H. Jones,et al.  Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. , 2002, Water research.

[26]  D. Barceló,et al.  Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments. , 2006, Talanta.